High-dimensional single-cell cytometry is routinely used to characterize patient responses 9 to cancer immunotherapy and other treatments. This has produced a wealth of datasets ripe 10 for exploration but whose biological and technical heterogeneity make them difficult to analyze 11 with current tools. We introduce a new interpretable machine learning method for single-cell 12 mass and flow cytometry studies, FAUST, that robustly performs unbiased cell population 13 discovery and annotation. FAUST processes data on a per-sample basis and returns biologically 14 interpretable cell phenotypes that can be compared across studies, making it well-suited for 15 the analysis and integration of complex datasets. We demonstrate how FAUST can be used for 16 candidate biomarker discovery and validation by applying it to a flow cytometry dataset from a 17 Merkel cell carcinoma anti-PD-1 trial and discover new CD4+ and CD8+ effector-memory T cell 18 correlates of outcome co-expressing PD-1, HLA-DR, and CD28. We then use FAUST to validate 19 these correlates in an independent CyTOF dataset from a published metastatic melanoma 20 trial. Importantly, existing state-of-the-art computational discovery approaches as well as prior 21 manual analysis did not detect these or any other statistically significant T cell sub-populations 22 associated with anti-PD-1 treatment in either data set. We further validate our methodology by 23 using FAUST to replicate the discovery of a previously reported myeloid correlate in a different 24 published melanoma trial, and validate the correlate by identifying it de novo in two additional 25 independent trials. FAUST's phenotypic annotations can be used to perform cross-study data 26 integration in the presence of heterogeneous data and diverse immunophenotyping staining 27 panels, enabling hypothesis-driven inference about cell sub-population abundance through a 28 multivariate modeling framework we call Phenotypic and Functional Differential Abundance 29 (PFDA). We demonstrate this approach on data from myeloid and T cell panels across multiple 30 trials. Together, these results establish FAUST as a powerful and versatile new approach for 31 unbiased discovery in single-cell cytometry. 32 * Corresponding author 1 Introduction 33 Cytometry is used throughout the biological sciences to interrogate the state of an individual's 34 immune system at the single-cell level. Modern instruments can measure approximately thirty 35 (via fluorescence) or forty (via mass) protein markers per individual cell [1, 2] and increasing 36 throughput can quantify millions of cells per sample. In typical clinical trials, multiple biological 37 samples are measured per subject in longitudinal designs. Consequently, a single clinical trial can 38 produce hundreds of high-dimensional samples that together contain measurements on many 39 millions of cells.
: Overview of FAUST. FAUST estimates annotation boundaries for an experimental unit and imputes missing boundaries in a two-stage process. An experimental unit is user-defined and can be a sample, stimulation condition, subject, batch, or site. Imputation is done according to a user-defined imputation-hierarchy and is useful to define classes of samples such as different tissues, batches, time points, or all samples. This schematic overview of FAUST assumes the experimental unit is an individual sample stained with a common panel of markers, while the imputation occurs across all samples in the experiment. A) To estimate annotation boundaries, FAUST grows an exhaustive forest of 1-dimensional, depth-3 gating strategies, constrained by shape: if, prior to depth-3, the cells in a node of the gating strategy have unimodal expression along all markers, the gating strategy along that path terminates. B) Annotation boundaries are estimated for markers within an experimental unit by averaging over gates drawn for that marker over the entire annotation forest. A "depth score" (Methods 4.4) is derived for each marker that quantifies the separation of the marker in each experimental unit. The distribution of scores across experimental units is used to determine whether a marker should be included in the discovery process and to determine the number of annotation boundaries a marker should receive. C) This procedure ensures that FAUST selects a standard set of markers for discovery and annotation as well as a standard number of annotation boundaries per selected marker. D) FAUST then conducts a search to discover and select phenotypes present in each experimental unit. Each discovered phenotype is given a score (described intuitively as a "price" in the main text) that quantifies the homogeneity of cells in an experimental unit with that phenotype; high-scoring phenotypes are then selected for annotation (Methods 4.8). Selected phenotypes are annotated using all selected markers from step C). E) FAUST returns an annotated count matrix with counts of cells in each phenotypic region discovered and selected in step D) that also survives down-selection by frequency of occurrence across experimental units. Figure 2 : FAUST annotations reflect underlying differences in protein expression not captured by dimensionality reduction. A) In a baseline responder's sample, the densities of per-marker fluorescence intensity for cells in the four correlates (different colors) as well as the entire nonnegative collection of live lymphocytes in the sample (gray) are compared. Cells used in density calculations are marked by tick marks and demonstrate that differences in cluster annotations reflect strict expression differences in the underlying data. B) A UMAP embedding computed from the same sample as panel A using the ten stated protein markers. All cells in the sample were used to compute the embedding. The embedding is colored by the relative intensity of observed PD-1 expression, windsorized at the 1st and 99th percentile, and scaled to the unit interval. The sample contains 271,219 cells, of which 72 were CD8+ PD-1 dim cells, 599 were CD8+ PD-1 bright cells, 673 were CD4 bright HLA-DR-CD28+ PD-1 dim cells, and 376 were CD4 bright HLA-DR+ CD28+ PD-1 dim cells. C) The same UMAP embedding highlighting the location of the cells from the four discovered sub-populations. The HLA-DR+ CD28+ PD-1 dim/bright effector memory CD8 T cells are in the dashed blue box; the HLA-DR+/-CD28+ PD-1 dim CD4 T cells, the solid red box. Exact phenotypes of the four sub-populations can be determined by matching the cluster color to panel A, and are also reported in figure 3. from patient tumor samples, described in [31] . Ten subjects passing clonality QC were common to 191 the two datasets, six of which were virus positive. Frequencies of the CD8+ FAUST populations 192 within these six subjects were strongly correlated (PD-1 dim ρ = 0.961; PD-1 Bright ρ = 0.823) 193 with the measurement of productive clonality ( Figure 3D ).
194
Together, these results lend support to the hypothesis that the CD8+ T cell correlates discovered 195 by FAUST in blood represents a circulating population of tumor-associated virus-specific T cells 196 that are also detectable in the tumor and whose presence in the tumor is known to correlate with 197 outcome. Due to the small sample size, this hypothesis must be confirmed on an independent, 198 larger set of MCC patient samples. However, since all four reported cell subsets ( Figure 3A ) 199 were detected without incorporating the viral status of each subject into the statistical model, these results also suggested more general hypotheses: increased abundance of the CD4+ or CD8+ 201 sub-populations discovered by FAUST is associated with positive response to pembrolizumab 202 therapy. We investigate these hypotheses in section 2.2. Figure 3 : Increased abundance of effector memory CD4/CD8 T cells co-expressing CD28, HLA-DR, and PD-1 is associated with positive response to anti-PD-1 therapy. A) Boxplots of the abundance of the four T cell sub-populations -with FAUST annotations reported at the top of each plot -associated with positive treatement outcome discovered by FAUST, stratified by (subjects' response to therapy. Bonferroni adjusted p-values reported contrasting all responders (n = 18) against all non-responders (n = 9). B) Boxplots of the abundance of the two CD8 T cell sub-populations stratified by their viral status, with interaction p-value reported. The two CD4+ T cell sub-populations are not presented because we did not observe a significant interaction between a subject's response to therapy and their viral status. C) The abundance of the two CD8+ T cell correlates among virus positive subjects against total PD-1 expression measured by IHC from tumor biopsies as described in [30] , with observed correlation in virus positive subjects (n=4) reported. D) The abundance of the two CD8+ T cell correlates among virus positive subjects plotted against productive clonality (1-normalized entropy) from tumor samples as described in [31] , with observed correlation in virus positive subjects (n=6) reported. detected significantly increased abundance of all three tested T cell phenotypes in responding 234 subjects ( Figure 4A -C). We note that in the CyTOF melanoma dataset, responders were defined 235 as patients that exhibited progression-free survival for at least 180 days after therapy [33]. This 236 analysis validated the associations detected by FAUST in the MCC trial, and highlights a powerful 237 feature of FAUST: performing targeted validation across studies and technologies.
238 Figure 4 : Significant FAUST phenotypes are validated in an independent melanoma trial. A) Boxplots of the abundance of effector memory CD8 T cells co-expressing CD28, HLA-DR, and PD-1 in unstimulated baseline samples for subjects that were treated with pembrolizumab, stratified by responder status, with Bonferroni-adjusted p-value reported (3 tests). B) The same as A, but displaying effector memory CD4 T cells co-expressing PD-1 and CD28. C) The same as A, but displaying effector memory CD4 T cells co-expressing PD-1, HLA-DR, and CD28. All subpopulations were targeted by first using FAUST to compute annotation boundaries for the listed markers within live intact singlets for each sample, and then using those boundaries to determine counts of cells with the stated phenotypes. All phenotypes matched the FAUST phenotypes from the MCC trial exactly, up to the number of annotation boundaries determined for each marker. changes in the abundance due to known technical effects. In the MCC anti-PD-1 trial, we examined all CD8+ T cells with the PD-1-bright FAUST phenotype. The temporal abundance of these cells is 246 shown in ( Figure 5A ) and reveals that these cells are not detectable in most samples after subjects 247 have received pembrolizumab therapy, presumably from pembrolizumab blocking the detecting 248 antibody. The observed decay post-treatment is consistent with the manual gating of CD3+ CD8+ 249 PD-1+ cells in this study (Supplementary Figure S1 ). 250 We also analyzed flow cytometry data from a second CITN trial: CITN-07 (NCT02129075, see 251 supplementary table S1 for trial data), a randomized phase II trial studying immune responses 
FAUST sub-populations capture underlying biological and technical sig-

266
These results demonstrate that FAUST is able to detect, annotate, and correctly assign abun-267 dance to cell sub-populations, even those sub-populations that are missing in some samples. 
FAUST robustly detects CD14+ signal across multiple immunotherapy
275 trials 276 Both the MCC anti-PD-1 and FLT3-L + therapeutic Vx trials had cytometry data stained with a 277 myeloid phenotyping panel. We also selected two myeloid phenotyping datasets (one CyTOF 278 discovery and one FACS validation assay) from a previously-published anti-PD-1 trial in metastatic 279 melanoma [9]. We will refer to these as the melanoma anti-PD-1 FACS and melanoma anti-PD-1 280 CyTOF datasets. We used FAUST to conduct unbiased discovery on these four datasets. A 281 principal finding of the published analysis of the melanoma anti-PD-1 trial was that the frequency 282 of CD14+ CD16-HLA-DR hi cells was associated with positive response to therapy. We wished 283 to determine if FAUST discovered phenotypes significantly associated with outcome that are 284 consistent with the published results across these four independent datasets.
285
In all datasets, we found that FAUST identified significant baseline phenotypes associated with 286 clinical outcome at the Bonferroni-adjusted 10% level that were consistent with the previously-287 published CD14+ CD16-HLA-DR hi phenotype (Figure 6 ). Complete phenotypes, effect sizes and confidence intervals for all myeloid baseline predictors discovered in the MCC anti-PD-1 myeloid 289 phenotyping data are in Supplementary Table S2 ; those discovered in the FLT3-L + therapeutic Vx 290 trial are in Supplementary Table S3 . All statistical models are fully described in section 4.
291
These results demonstrate the power of our approach to detect candidate biomarkers in a 292 robust manner across different platforms, staining panels, and experimental designs. They also 293 highlight that the complete phenotypes discovered by FAUST may not be directly comparable 294 across datasets due to differences in the marker panels. However, the sub-phenotype CD14+ CD16-295 HLA-DR+/bright CD3-CD19-CD56-is contained within the marker panels of the three flow 296 cytometry datasets, naturally raising the question: is this sub-phenotype differentially abundant 297 across the datasets? This desire to test specific hypotheses across datasets led us to develop two 298 analysis methods which we describe in section 2.5. hypothesize that total CD4 and total CD8 T cells expressing PD-1 are elevated in responders at CD16-HLA-DR+/bright CD3-CD56-CD19-results, there is less heterogeneity detected within 360 the phenotype-of-interest across the studies, and both the top-down approach and PFDA detect 361 increased abundance in responding subjects (Figure 7B,D) . Together, these results demonstrate 362 two ways that FAUST enables targeted hypothesis testing of pre-specified phenotypes, which 363 in turn makes it possible to use FAUST to carry out validation analyses as well as to integrate 364 findings across studies through PFDA. 365 Figure 7 : FAUST phenotypes enable cross-study meta-analysis of datasets stained with disparate marker panels. A) Myeloid phenotyping marker panels from three trials. A marker with a green box is present in the stated trial; a marker with a gray box, absent. B) Box plots displaying targeted counts for CD14+ CD16-HLA-DR+/bright CD3-CD56-CD19-phenotypes across three trials. C) Box plots displaying targeted counts for CD3+ CD4 Bright CD8-PD-1 dim or bright and CD3+ CD4-CD8+ PD-1 dim or bright phenotypes in the MCC trial T cell panel. D) Forest plots displaying one-sided 95% confidence intervals (CIs) for increased abundance of CD14+ CD16-HLA-DR+/bright CD3-CD56-CD19-phenotypes in responders vs. non-responders for three trials. In each panel, we first show CIs derived from fitting the univariate model to each CD14+ CD16-HLA-DR FAUST phenotype. We then show the 95% CI derived by fitting a " PFDA" model jointly to the FAUST populations, and then testing for increased abundance using model coefficients. E) Similar forest plots to those described in D), for CD3+ CD4 Bright CD8-PD-1 dim or bright and CD3+ CD4-CD8+ PD-1 dim or bright phenotypes in the MCC trial T cell panel. Unadjusted p-values are also reported in panels B,C,D,E. goal was to test how robust FAUST's findings were to different data transformations and different 370 selection of samples. Our second goal was to test if other methods detected significant correlates 371 with anti-PD-1 therapy in baseline samples.
372
In this re-analysis, we ran each method on live lymphocytes from all 78 experimental samples 373 as well as from the 27 baseline samples alone. To test performance under different data transfor-374 mations, we transformed samples using the biexponential map (used for analysis in section 2.1) 375 as well as inverse hyperbolic sine with co-factor 120 (the transformation reported in [5] ). For all 376 methods, we tested clusters for differential abundance between responders and non-responders 377 in baseline samples using the same binomial GLMM employed in section 2.1 (equation (4.5)).
378
For FlowSOM and Phenograph, samples were concatenated before clustering, and we set tuning 379 parameters to the settings reported in [5] . After testing for differential abundance between respon-380 ders and non-responders, no clusters defined by FlowSOM or Phenograph were associated with 381 response to therapy at the Bonferroni-adjusted 20% level or the FDR-adjusted 20% level (Table S5 ).
382
On the other hand, across all re-analysis settings FAUST defined an effector memory CD8+ T cell 383 cluster co-expressing CD28, HLA-DR, and PD-1, as well as an effector memory CD4+ T cell cluster 384 co-expressing CD28 and PD-1, and both were associated with response to therapy at baseline at 385 the Bonferroni-adjusted 10% level across all re-analysis settings (Table S5 ). 386 We also conducted an in silico study that simulated the discovery process in cytometry data 387 analysis by inducing a differentially abundant population associated with a simulated response to 388 therapy, in datasets generated from a variety of mixture models (Supplementary Section A.13) . 389 We compared FAUST to FlowSOM in this study since FlowSOM is computationally efficient and 390 is recommended in the review [5] . Across simulation settings, we found that FAUST consistently 391 discovered the phenotype whose increased abundance in a subject was causally linked (by If pre-gating has not been performed by an investigator, computational methods [34, 41] can 464 be used before applying FAUST to cytometry data in order to guarantee this assumption is met.
465
Assumption 2. In each sample, measurements on the live cells are made using a common set of p 466 transformed protein markers.
467
Let n i denote the number of events in the i th experimental unit. FAUST supposes each event E i,j in an experimental unit E i , of dimension p (the number of markers), arises as a sample from a finite mixture model
ω m · f m,i , (4.1)
for 1 ≤ j ≤ n i , with M ∈ N, 0 ≤ ω m ≤ 1 and ∑ M m=1 ω m = 1 for all 1 ≤ i ≤ n. FAUST assumes the mixture components f m,i of an experimental unit in (4.1) are translated and scaled versions of a common collection of densities on the space of protein measurements: for all 1 ≤ i ≤ n and
for each experimental unit i, with the common class F is defined as 
where, abusing notation, we let 535 α R ≡ α R (N m,j ) ≡ the dip test p-value in the root population of the gating strategy that led to N m,j .
We allow α C and α G to be defined similarly. The function Q can be interpreted as a measure of the 536 quality of the gating strategy that led to node N m,j . In the case of a grandchild node that had clear Finally, define
The depth score is defined to be the normalized sum
.
(4.4) The depth score maps N m into [0, 1], with at least one marker in a gated sample achieving 543 the maximal score of 1. This is taken as a measure of separation quality: the best scoring marker 544 according to the depth score is taken to be the best separated marker in that sample at the root 545 population, and conditionally along all other gating strategies. Normalizing to the unit interval 546 allows depth scores to be compared across experimental units for given markers. By using the 547 factorial weights δ i , the depth score also explains why FAUST only explores gating strategies 548 involving, at most, combinations of three markers in its scoring and marker selection phase.
549
Adding more combinations of markers induces a factorial increase in computational cost. But any 550 marker that enters a gating strategy at depth 4 (or beyond) will be dominated in depth score by 551 those markers initially gated in the annotation forest at or near the root population. Consequently, 552 after normalization in experiments with a large number of markers, such markers have depth 553 score an above zero, and are effectively never selected by FAUST for discovery and annotation.
554
Hence the restriction to 3-marker gating strategies.
FAUST method: annotation boundary estimation 556
The depth score is also used to estimate annotation boundaries. Recalling FAUST only explores 557 gating strategies with 4 or fewer annotation boundaries, FAUST partitions the set 
FAUST selects the number of annotation boundaries for the marker m by choosing the set G j with 562 the maximal sum ∑ N∈G j ω(N). Letting g 1 (N m,j ) denote the smallest gate location estimated by 563 the taut string in node N m,j (which is the only gate location if FAUST selects G 1 ), FAUST estimates 564 the phenotypic boundary locations for the marker by taking the weighted average 565 ∑ N∈G j ω(N)g 1 (N)
In the event FAUST selects G j , j > 1 (i.e., multiple annotation boundaries), similar weighted 566 averages are taken for g 2 (N m,j ), etc. we assume c i,k ∼ Binomial(n i , µ i,k ). Our model is
where Responder is an indicator variable equal to 1 when the subject exhibits complete or partial 679 response to therapy, and 0 otherwise, and each ξ i,k ∼ N(0, σ 2 i,k ) is a subject-level random effect.
phenotypes corresponding to significant phenotypes discovered in the MCC anti-PD-1 trial (Section 749 2.1) were targeted in each sample using the standardized boundaries. This produced counts for 750 two cell populations. Counts from these two cell populations were taken from the 40 samples 751 from subjects that went on to receive anti-PD-1 therapy, and tested for association with response 752 to therapy. The model used here is identical to (4.5), mutatis mutandis. FAUST phenotypes within a given study. Let n denote the number of subjects at baseline, and N = n · k * . For 1 ≤ i ≤ N, 1 ≤ j ≤ k * our statistical model is
β c,j · Cluster i,j + β i,j · Cluster i,j · Responder i + ξ i , (4.6)
where Cluster i,j is an indicator variable that is 1 when observation i is from cluster j and 0 otherwise, Responder i is an indicator variable when observation i is taken from a responding subject, and η i ∼ N(0, σ 2 i ) is an observation-level random effect. After estimating model coefficients β i,j in (4.6), we test for differential abundance by testing t for positivity of linear combination of the coefficients:
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